Thursday, April 2, 2026
23.1 C
Bengaluru

A Social Experiment

MedicinMan May 2015

[wpfilebase tag=file id=47 tpl=download-button /]

Inside this Issue

1. Doctor Profiling for Sales Success by RB Balakrishna

A Doctor Profile enables the Medical Rep to tailor-make his detailing approach to each Doctor, ensuring sales success.

2.  Using Gamification to Achieve a State of Flow while Learning by Rajiv Jayaraman

By turning learning into a game, learners enter into a ‘state of flow’ – a condition where the ‘high’ of the game makes learning a habit.

3.  The 3 ‘E’s of Sales Leadership: Engage,  Empower &  Enable by K. Hariram

How to move from being mere sales ‘managers’ to being sales ‘leaders’.

4.  Focus Feature: Brand Life Cycle Management by Vivek Hattangadi

With few new chemical entities in the pipeline, pharma companies will have devote more attention to managing the life cycle of their brands to derive maximum mileage from existing products.

5.  Lost Patients by Hanno Wolfram

By ignoring the pharmacist, pharma companies are losing out on meeting the health needs of many patients.

Hot this week

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Topics

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...
spot_img

Related Articles

spot_imgspot_img
Previous article
Next article